Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 4/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2379763 | 1.00 | CHRM1 (0.49) | CHRM1CNR1CNR2GSK3BDYRK1A | |
| SCHEMBL2901294 | 1.00 | CHRM1 (0.49) | CHRM1CNR1CNR2GSK3BDYRK1A | |
| SCHEMBL8038153 | 0.98 | CHRM1 (0.48) | CHRM1CNR1CNR2GSK3BDYRK1A | |
| Hydrochloric Acid SCHEMBL28577068 | 0.98 | CHRM1 (0.48) | CHRM1CNR1CNR2GSK3BDYRK1A | |
| Hydrochloric Acid SCHEMBL28577066 | 0.98 | CHRM1 (0.48) | CHRM1CNR1CNR2GSK3BDYRK1A | |
| Hydrochloric Acid SCHEMBL28915471 | 0.98 | CHRM1 (0.48) | CHRM1CNR1CNR2GSK3BDYRK1A | |
| SCHEMBL20434091 | 0.83 | CYP1A2 (0.48) | CHRM1GSK3BDYRK1ACYP1A2TDP1 | |
| SCHEMBL15431899 | 0.83 | CYP1A2 (0.48) | CHRM1GSK3BDYRK1ACYP1A2TDP1 | |
| SCHEMBL17625631 | 0.83 | CYP1A2 (0.48) | CHRM1GSK3BDYRK1ACYP1A2TDP1 | |
| SCHEMBL4492046 | 0.81 | CHRM1 (0.44) | CHRM1CNR1CNR2GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112996784-B | Indole derivatives and their use in medicine | 北京越之康泰生物医药科技有限公司 | 2023-05-30 | — | — | CN | disclosed |
| WO-2022170917-A1 | POLYCYCLIC PYRIMIDINE DERIVATIVE AS SOS1 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州阿尔脉生物科技有限公司 | 2022-08-18 | — | — | WO | disclosed |
| US-11358949-B2 | Carbamate and urea compounds as multikinase inhibitors | ANGEX PHARMACEUTICAL, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| CN-112996784-A | Indole derivatives and their use in medicine | 北京越之康泰生物医药科技有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-20210163445-A1 | CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS | ANGEX PHARMACEUTICAL, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION | 2020-04-02 | — | — | US | disclosed |
| WO-2020057403-A1 | INDOLE DERIVATIVE AND MEDICAL APPLICATION THEREOF | 北京越之康泰生物医药科技有限公司 | 2020-03-26 | — | — | WO | disclosed |
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| CN-101917981-A | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP | 2010-12-15 | — | — | CN | disclosed |
| EP-2217226-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
| WO-2009061879-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | MAN2B1, GAA, GBA1 | CHRM1 3877/4885CNR1 3836/4885CNR2 4270/4885 |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DPEP1, DHPS | CHRM1 4857/4885CNR1 4795/4885CNR2 4814/4885 |
| US-11358949-B2 | Carbamate and urea compounds as multikinase inhibitors | UCK2, ULK2, CDK9 | CHRM1 4368/4885CNR1 2744/4885CNR2 2554/4885 |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, PADI3 | CHRM1 4835/4885CNR1 4747/4885CNR2 4773/4885 |
| US-20210163445-A1 | CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS | UCK2, ULK2, CDK9 | CHRM1 4368/4885CNR1 2744/4885CNR2 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.